<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">The effect of antibiotic use on prevalence of nosocomial vancomycin-resistant enterococci-an ecologic study</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Cornelius</forename><surname>Remschmidt</surname></persName>
							<email>cornelius.remschmidt@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Behnke</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Axel</forename><surname>Kola</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Luis</forename><forename type="middle">A Peña</forename><surname>Diaz</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anna</forename><forename type="middle">M</forename><surname>Rohde</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petra</forename><surname>Gastmeier</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Schwab</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Hygiene and Environmental Medicine</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Hindenburgdamm 27</addrLine>
									<postCode>12203</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">The effect of antibiotic use on prevalence of nosocomial vancomycin-resistant enterococci-an ecologic study</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">BFA84C5BC7ECBCC7CB462F3CE79346BD</idno>
					<idno type="DOI">10.1186/s13756-017-0253-5</idno>
					<note type="submission">Received: 28 April 2017 Accepted: 4 September 2017</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:50+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Vancomycin-resistant enterococcus</term>
					<term>Transmission</term>
					<term>Antibiotic use</term>
					<term>Carbapenems</term>
					<term>Glycopeptides</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background: Vancomycin-resistant enterococci (VRE) are among the most common antimicrobial-resistant pathogens causing nosocomial infections.</s><s>Although antibiotic use has been identified as a risk factor for VRE, it remains unclear which antimicrobial agents particularly facilitate VRE selection.</s><s>Here, we assessed whether use of specific antimicrobial agents is independently associated with healthcare-associated (HA) VRE rates in a university hospital setting in Berlin, Germany.</s><s>Methods: We conducted the study between January 2014 and December 2015 at the Charité-university hospital of Berlin, Germany.</s><s>From the hospital pharmacy, we extracted data for all antibacterials for systemic use (anatomical therapeutic chemical (ATC)-classification J01) and calculated ward specific antibiotic consumption in defined daily doses (DDDs) per 100 patient-days (PD).</s><s>We used the microbiology laboratory database to identify all patients with isolation of invasive or non-invasive VRE and calculated HA-VRE incidence as nosocomial VREcases per 100 patients and HA-VRE incidence density as nosocomial VRE-cases per 1000 PD.</s><s>We defined VRE isolates as hospital-acquired if they were identified three days or later after hospital admission and otherwise as community-acquired (CA-VRE).</s><s>We performed univariable and multivariable regression analyses to estimate the association of the frequency of HA-VRE per month with antibiotic use and other parameters such as length of stay, type of ward or presence of at least one CA-VRE on ward.</s><s>In a second analysis, we considered only patients with VRE infections.</s><s>Results: We included data from 204,054 patients with 948,380 PD from 61 wards.</s><s>Overall, 1430 VRE-cases were identified of which 409 (28.6%) were considered hospital-acquired (HA).</s><s>We found that carbapenem use in the current month and prior-month use of glycopeptides increased the risk for HA-VRE by 1% per 1 DDD/100 PD and 3% per 1 DDD/100 PD, respectively.</s><s>However, when only VRE from clinical samples were considered, only glycopeptide use showed a statistically significant association.</s><s>In both models, detection of at least one patient with CA-VRE on a ward in the current month significantly increased the risk of HA-VRE, thereby indicating nosocomial spread of VRE.</s><s>Conclusions: Our findings suggest that the risk of HA-VRE is associated with specific antimicrobial agents.</s><s>Prudent use of these antimicrobial agents might reduce nosocomial VRE rates.</s><s>That appearance of at least one CA-VRE case on the ward increased the risk of HA-VRE detection highlights the importance of strict hand hygiene practices to interrupt person-to-person transmission of VRE.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Background</head><p><s>Vancomycin-resistant enterococci (VRE) are emerging worldwide and are among the most common antimicrobialresistant pathogens causing nosocomial infections <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref>.</s><s>Since infections with VRE are associated with prolonged inhospital stay and excess mortality <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b5">6]</ref>, increasing VRE rates pose a serious threat to global health.</s><s>In fact, the World Health Organization (WHO) judged VRE to be of high importance in the "Global Priority list of antibioticresistant bacteria to guide research, discovery and development of new antibiotics" <ref type="bibr" target="#b6">[7]</ref>.</s></p><p><s>So far, several risk factors for VRE colonization or infection have been identified, such as long periods of hospitalization, immunosuppression, serious comorbid conditions, close proximity to patients infected or colonized with VRE as well as antibiotic use <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref>.</s><s>Although antibiotic use has been advocated as a major modifiable risk factor <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b12">13]</ref>, controversies remain regarding the impact of specific antimicrobial agents or antimicrobial groups on the selection process of VRE <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b11">12]</ref>.</s></p><p><s>Therefore, the primary objective of the study was to investigate whether use of specific antimicrobial agents is independently associated with nosocomial VRE rates in a university hospital setting in Berlin, Germany.</s><s>Secondary objective was to identify other risk factors that are associated with nosocomial VRE rates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>This study was conducted at the Charité-university hospital of Berlin, between January 2014 and December 2015.</s><s>The Charité is a tertiary care center with more than 3000 beds and more than 140,000 inpatient cases per year.</s></p><p><s>From the microbiology laboratory database of Charité we prospectively identified patients with vancomycinresistant Enterococcus (E.) faeciumor E. faecalis-isolates from intensive care units (ICUs) and surgical, medical and hemato-oncological wards.</s><s>In case of screening samples, selective chromogenic medium (chromID® VRE, bioMérieux) and VITEK 2 system (bioMérieux) were used, while clinical samples were processed following standard procedures dependent on specimen type.</s><s>Results were interpreted according to European Committee on Antimicrobial Susceptibility Testing definitions (EUCAST, http://www.eucast.org).</s><s>A molecular characterization of the VRE isolates was not performed.</s></p><p><s>We defined VRE isolates as hospital-acquired (HA-VRE) if they were identified three days or later after hospital admission and otherwise as community-acquired (CA-VRE).</s><s>In patients with multiple VRE isolates during the same hospital stay, only the first identified isolate was considered.</s><s>We included isolates irrespective whether they were obtained for infection control surveillance or recovered from clinical specimen and irrespective whether they were associated with colonization or infection.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Performance of screening</head><p><s>At the Charité, a targeted risk adjusted screening policy is implemented: in patients in whom a VRE has been isolated within the previous three years, a rectal swab is obtained at admission.</s><s>However, during the study period eight (non-ICU) wards performed an intensified admission screening that involved all patients irrespective of underlying risk factors.</s><s>In this ecologic study, we did not collect data on compliance with the screening policy or compliance with hand hygiene or cleaning procedures on the respective wards.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic antibiotic use</head><p><s>Antimicrobial agents were classified according to the anatomical therapeutic chemical (ATC) system (34).</s><s>From the pharmacy of Charité, ward specific data on antibiotic consumption were converted into defined daily doses (DDDs) and reported as DDD/100 patientdays (PD) at monthly intervals.</s><s>We collected data for all antibacterials for systemic use (ATC-code J01).</s><s>Data on antifungal or antiviral medication were not considered.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics and data protection</head><p><s>For this ecologic study, we analyzed aggregated and anonymous data that were collected by the hospital in accordance with the German "Protection against Infection Act", §23.</s><s>Therefore, ethical approval and informed consent were not required and institutional review boards were not consulted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p><s>We calculated median and interquartile range (IQR) for the total study period (24 months) for the following variables: number of patients, patient-days (PD), average length of stay (LOS), number of beds per ward, bed occupancy rate, month of VRE-detection, HA-VRE rates and antibiotic use.</s><s>HA-VRE incidence was calculated as nosocomial VRE-cases per 100 patients and HA-VRE incidence density as nosocomial VRE-cases per 1000 PD.</s><s>We reported data for all wards as well as stratified by type of ward (i.e.</s><s>surgical, medical, ICU, hematooncological).</s><s>Differences in baseline characteristics between different types of wards were compared by using the Kruskal-Wallis test.</s><s>Univariable and multivariable regression using generalized linear models was performed to estimate the association of the frequency of HA-VRE per month with different antimicrobial groups in the current month and the month before the current month and further confounding parameters such as length of stay (LOS), bed occupancy (patient days/bed places on ward available), type of ward and at least one patient with community-acquired VRE on ward in the current month.</s><s>In addition, we added a variable that took the different screening policies (screening of all patients on admission irrespective of underlying risk factors on eight wards) into account.</s><s>Since observations within a ward are not statistically independent due to the diagnostic and management policies (particularly the frequency of microbiological tests and screening), adjusted incidence rate ratios (IRR) with 95% confidence intervals (CI) were estimated.</s><s>They were based on generalized estimating equation (GEE) models which account for this clustering effect by using an exchangeable correlation structure (35).</s></p><p><s>We used negative-binomial distribution instead of Poisson distribution because the variance exceeds the mean and overdispersion was observed.</s><s>The Lagrange multiplier test was used to test whether the negative binomial model significantly differs from the Poisson model.</s><s>The log number of patient days during each month was used as an offset in the model.</s><s>All parameter with p &lt; 0.2 in the univariable regression model were included in a full model and then non-significant parameters were excluded stepwise.</s><s>The selection criterion was the smallest Chi-square value and p ≥ 0.05 in the type III score statistic.</s><s>The quasi-likelihood information criterion (QIC) as a modification of the Akaike information criterion (AIC) was used as goodness-of-fit measure in the GEE model.</s><s>We calculated two models.</s><s>The first model considered all identified HA-VRE isolates (clinical and screening samples) the second model considered only clinical specimen.</s><s>Antimicrobial agents that are relevant for the treatment of VRE, such as daptomycin, linezolid and tigecyclin were excluded from the analysis.</s><s>Additionally, spearman correlation coefficients were calculated between the antibiotic use and the incidence density of HA-VRE for the entire study period (24 months).</s><s>P-values less than 0.05 were considered significant.</s><s>All analyses were performed using SPSS [IBM SPSS statistics, Somer, NY, USA] and SAS 9.4 [SAS Institute, Cary, NC, USA].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>From 61 wards (20 surgical, 18 medical, 14 ICUs, 9 hemato-oncological) we included data from 204,054 patients with 948,380 patient-days.</s><s>Median length of stay was 4.7 days (IQR, 3.9-5.8)</s><s>and was statistically significant higher in ICUs and hemato-oncological wards as compared to surgical wards (see Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rates of HA-VRE</head><p><s>Overall, 1430 VRE-cases were identified of which 409 (28.6%) were considered hospital-acquired.</s><s>Of those, 238 (58.2%)</s><s>HA-VRE were identified in 2015.</s><s>The median HA-VRE incidence and HA-VRE incidence density in all 61 wards was 0.11 (IQR, 0.03-0.32)</s><s>and 0.24 (0.07-0.54), respectively (Table <ref type="table" target="#tab_0">1</ref>); however, rates of HA-VRE differed significantly between types of ward.</s><s>Highest HA-VRE rates were observed on ICUs (incidence density: 1.17 (0.71-1.75)) and lowest HA-VRE rates on medical wards (incidence density: 0.07 (0-0.22)).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Systemic antibiotic use</head><p><s>Between 2014 and 2015 median antibiotic use among all wards was 76.8 (IQR, 61.6-131.9)</s><s>DDD/100 PD.</s><s>Antibiotic use ranged from 64.1 DDD/100 PD on medical wards to 163.2 DDD/100 PD on ICUs (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>Particularly, the use of broad-spectrum antibiotics such as third-generation cephalosporins, glycopeptides and carbapenems was 3 to 13-fold higher on ICUs as compared to medical or surgical wards.</s><s>For example, median carbapenem use on medical wards was 3.2 (1.5-8.4)</s><s>DDD/100 PD, whereas it was 42.3 <ref type="bibr">(22.5-49.4</ref>)</s><s>DDD/100 PD on ICUs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Associations between HA-VRE and antibiotic use</head><p><s>According to Spearmans correlation, several antimicrobial groups were associated with HA-VRE incidence density.</s><s>For example, carbapenem use (r = 0.801, p &lt; 0.001, ATC code J01DH), glycopeptide use (r = 0.76, p &lt; 0.001, ATC code J01XA) and use of third-generation cephalosporines (r = 0.57, p &lt; 0.001, ATC code J01DD) showed a strong correlation with HA-VRE incidence density (see Fig. <ref type="figure" target="#fig_0">1</ref>).</s></p><p><s>The first multivariable regression model (screening and clinical specimen) indicated that carbapenem use in the current month independently increased the risk for HA-VRE by 1% per 1 DDD/100 patient-days (incidence rate ratio (IRR), 1.01; 95% confidence interval (CI) 1.00-1.02,</s><s>p &lt; 0.01), see Table <ref type="table" target="#tab_1">2</ref>. Glycopeptide use in the previous month but not in the current month was also associated with an increased risk of HA-VRE (IRR 1.03; 95% CI, 1.01-1.05,</s><s>p &lt; 0.01).</s><s>In addition, type of hospital ward (ICU and hemato-oncological ward vs. surgical ward), detection of at least one patient with CA-VRE in the current month, an intensified screening policy and the year 2015 were independently associated with higher VRE rates.</s></p><p><s>The second multivariable regression model considering only VRE from clinical specimen showed that glycopeptide use in the previous month (IRR 1.03, 95% CI 1.01-1.05,</s><s>p &lt; 0.01) were the only antimicrobial agent that was statistically significant associated with HA-VRE (see Table <ref type="table" target="#tab_2">3</ref>).</s><s>Furthermore, being hospitalized on an ICU, detection of at least one patient with CA-VRE in the current month and the year 2015 increased the risk for HA-VRE.</s></p><p><s>In both multivariable models, size of ward, length of stay and bed occupancy rate were no independent risk factors for HA-VRE in the final models.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Antibiotic use is one of the most important risk factors for VRE occurrence within the hospital setting <ref type="bibr" target="#b12">[13]</ref>.</s><s>Although specific antimicrobial agents such as piperacillin/tazobactam <ref type="bibr" target="#b13">[14]</ref> or ceftriaxone <ref type="bibr" target="#b14">[15]</ref> or antimicrobial groups such as glycopeptides, third-generation cephalosporines and fluoroquinolones <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> have been found to be associated with increasing VRE prevalence, controversies remain.</s><s>For example, although a large prospective study found that vancomycin was strongly associated with increased prevalence of VRE <ref type="bibr" target="#b17">[18]</ref>, a systematic review that assessed the impact of reducing vancomycin use on the prevalence and incidence of VRE colonization in the US did not find a positive effect of such It is unclear, why among antimicrobial groups only glycopeptides but not carbapenems were associated in both models with HA-VRE rates.</s><s>A possible explanation is that glycopeptide use constitutes only a first step in the selection process of VRE: Although glycopeptide exposure does not promote emergence of VRE through genetic mutations in individual patients, it might facilitate selection of intestinal VRE <ref type="bibr" target="#b7">[8,</ref><ref type="bibr" target="#b12">13]</ref>.</s><s>In a second step, use of specific antimicrobial agents further influences the microbial balance leading to high-density colonization with VRE at detectable levels <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b19">20]</ref>.</s></p><p><s>In fact, Donskey et al. showed that in patients colonized with VRE exposure to antimicrobial agents with activity against Gram-negative bacteria or with antianaerobic activity leads to a rapid increase of intestinal VRE density, whereas discontinuation of these antibiotics decreased VRE density <ref type="bibr" target="#b20">[21]</ref>.</s><s>Since fecal density of VRE directly affects the sensitivity of screening results, active surveillance (i.e.</s><s>rectal screening) for VRE at hospital admission might lead to false-negative results in patients with low VRE densities <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b22">23]</ref>.</s><s>In case that VRE-related precaution measures are not implemented, this may contribute to increased spread of VRE within hospitals, particularly if antibiotic therapy is initiated <ref type="bibr" target="#b20">[21]</ref>.</s><s>However, for clinical infections other factors such as immunosuppression or hygiene practices might be more important, factors that were only indirect (ward type ICU; presence of at least one CA-VRE on ward) assessed in our study.</s></p><p><s>It is also unclear, why carbapenem use in the current but not in the prior month was associated  with HA-VRE-rates when screening and clinical specimen were considered.</s><s>However, given the available evidence it seems unlikely that a single antimicrobial agent is responsible for the multifactorial process of VRE selection.</s><s>It is rather an interaction of different antimicrobial agents with the competing intestinal microbiota and might differ from individual to individual <ref type="bibr" target="#b7">[8]</ref>.</s></p><p><s>Regarding antibiotics, the use of broad-spectrum antibiotics such as glycopeptides and carbapenems was 3 to 13-fold higher on ICUs as compared to medical or surgical wards.</s><s>Although interpreting these results without individual patient data is challenging, this rates might indicate inappropriate use of these antibiotics on ICUs.</s><s>Antibiotic stewardship could limit unnecessary or inappropriate use of antibiotics, thereby improving the quality of antibiotic use in hospitals <ref type="bibr" target="#b23">[24]</ref>.</s></p><p><s>In addition to glycopeptides carbapenems, we found that hospitalization on an ICU as well as detection of CA-VRE increased the risk of HA-VRE acquisition.</s><s>These results are in line with other studies that found that hospitalization on ICUs or severe underlying comorbidities and immunosuppression are risk factors for VRE colonization or infection <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b24">25]</ref>.</s><s>That appearance of at least one CA-VRE case on the ward almost doubled the risk of HA-VRE detection highlights the importance of strict hand hygiene practices for health care workers to interrupt person-to-person transmission <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref>.</s></p><p><s>The fact that HA-VRE cases increased from 2014 to 2015 might indicate an epidemiological trend that has been already observed in other studies <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30]</ref>; however, the situation regarding spread of VRE in Europe is diverse <ref type="bibr" target="#b0">[1]</ref>.</s><s>Since data in our study were collected for only two years, these results have to be interpreted with caution.</s></p><p><s>Our study has several limitations.</s><s>First, we used an ecological study design, which can give valuable insights in understanding the association between antibiotic use and VRE selection; however, causality cannot be proven.</s></p><p><s>Second, we analyzed aggregated data on ward level and had no data on individual patients.</s><s>Therefore, controlling for important confounders, such as duration of antibiotic therapy, history of antibiotic exposure or severity of underlying illness was not possible.</s><s>Since it has been shown that group-level and individual-patient-level analyses might yield different results when the association between antibiotic exposure and resistance is assessed <ref type="bibr" target="#b30">[31]</ref>, our results have to be interpreted with caution.</s><s>Third, routine screening for VRE at hospital admission was implemented only on some wards at Charité.</s><s>Patients from other wards may have been colonized on admission or may have acquired VRE in outside hospitals.</s><s>Therefore, the proportion of HA-VRE might be overestimated <ref type="bibr" target="#b31">[32]</ref>.</s><s>Fourth, the DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults and does not necessarily reflect the recommended or prescribed daily dose <ref type="bibr" target="#b32">[33]</ref>.</s><s>Fifth, a molecular characterization of the identified VRE was not performed and we could not exclude clonal dissemination on the respective wards; however, since we did not identify VRE cluster on ward level during the study period, large outbreaks seems unlikely.</s><s>Finally, data on compliance with hand hygiene and cleaning procedures were not measured, therefore confounding effects of these factors on our results are unknown.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>In conclusion, we found a positive correlation between prior-month use of glycopeptides and current use of carbapenems and the incidence of HA-VRE on ward level when invasive and non-invasive VRE were considered.</s><s>In addition, detection of at least one patient with CA-VRE in the current month significantly increased the risk of nosocomial acquisition of VRE, thereby indicating the risk of person-to-person transmission of VRE.</s><s>To this end, a multifaceted approach to lower HA-VRE rates is required including prudent use of antimicrobial agents as well as implementation of and strict compliance to infection control measures to prevent VRE transmission.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 incidence density of hospital-acquired vancomycin resistant enterococci (ID HA-VRE) and antibiotic use density (DDD/100pd) of carbapenems (ATC-code J01DH, Spearman correlation coefficient r = 0.801, p &lt; 0.001) and glycopeptides (ATC code J01XA, r = 0.76, p &lt; 0.001) on 61 wards, 2014-2015, Berlin, Germany</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Descriptive data, VRE cases and antibiotic use of the 61 wards considered in the analysis in total and by type of ward</s></p></div></figDesc><table><row><cell>Characteristic</cell><cell cols="2">Type of hospital ward</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Baseline characteristics</cell><cell>All (n = 61)</cell><cell>Surgical (n = 20)</cell><cell>Medical (n = 18)</cell><cell>Intensive Care Unit</cell><cell>Hemato-oncological</cell></row><row><cell></cell><cell>Median (IQR)</cell><cell>N (%)/median (IQR)</cell><cell>N (%)/median (IQR)</cell><cell>(n = 14)</cell><cell>(n = 9)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>N (%)/median (IQR)</cell><cell>N (%)/median (IQR)</cell></row><row><cell>Patients, N = 204,054</cell><cell cols="2">3260 (1886-4478) 4180 (2642-5002)</cell><cell>3849 (3486-4909)</cell><cell>1483 (1252-1899)</cell><cell>2031 (1576-2268)</cell></row><row><cell>Patient-days, N = 948,380</cell><cell>14,773 (10,642-</cell><cell>16,488 (13,488-</cell><cell>17,912 (15,018-</cell><cell>8949 (6961-</cell><cell>13,722 (10,849-</cell></row><row><cell></cell><cell>19,154)</cell><cell>19,819)</cell><cell>20,758)</cell><cell>10,642)</cell><cell>14,430)</cell></row><row><cell>Average length of stay, d</cell><cell>4.7 (3.9-5.8)</cell><cell>4.4 (3.7-5.0)</cell><cell>4.3 (3.7-5.1)</cell><cell>5.6 (5.1-7.0)</cell><cell>6.4 (4.8-8.2)</cell></row><row><cell>Beds, N = 1604</cell><cell>27 (18-32)</cell><cell>32 (30-33)</cell><cell>31.5 (26-36)</cell><cell>13 (10-16)</cell><cell>21 (18-21)</cell></row><row><cell>Bed occupancy rate (bed-days/patient-</cell><cell>81.1 (77.4-92.6)</cell><cell>77.2 (67.0-81.5)</cell><cell>79.1 (78.0-82.4)</cell><cell>94.9 (94.0-97.2)</cell><cell>89.5 (81.1-93.1)</cell></row><row><cell>days*100)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VRE rates</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>VRE cases (all a ), N = 1430</cell><cell>12 (5-24)</cell><cell>5.5 (4.5-12.5)</cell><cell>7 (3-15)</cell><cell>20 (13-70)</cell><cell>48 (33-69)</cell></row><row><cell>Screening cases, N = 939 (65.7%)</cell><cell>4 (2-12)</cell><cell>3.5 (1.5-5)</cell><cell>3.5 (2-4)</cell><cell>9 (0-26)</cell><cell>42 (31-63)</cell></row><row><cell>Clinical cases, N = 491 (34.3%)</cell><cell>4 (2-10)</cell><cell>4 (1.5-6.5)</cell><cell>3 (1-8)</cell><cell>12.5 (8-23)</cell><cell>3 (2-6)</cell></row><row><cell>VRE cases (nosocomial), N = 409 (28.6%)</cell><cell>3 (1-7)</cell><cell>2 (1-4)</cell><cell>1 (0-4)</cell><cell>11.5 (5-21)</cell><cell>5 (3-8)</cell></row><row><cell>VRE incidence (nosocomial VRE/100 patients)</cell><cell>0.11 (0.03-0.32)</cell><cell>0.05 (0.02-0.14)</cell><cell>0.03 (0-0.11)</cell><cell>0.68 (0.32-1.22)</cell><cell>0.29 (0.14-0.53)</cell></row><row><cell>VRE incidence density (nosocomial VRE/ 1000</cell><cell>0.24 (0.07-0.54)</cell><cell>0.11 (0.06-0.27)</cell><cell>0.07 (0-0.22)</cell><cell>1.17 (0.71-1.75)</cell><cell>0.35 (0.24-0.54)</cell></row><row><cell>patient-days)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Systemic antibiotic use (ATC-code) in DDD/100 patient-days</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>All antibacterials for systemic use (J01)</cell><cell cols="2">76.8 (61.6-131.9) 72.8 (58.1-83.6)</cell><cell>64.1 (39.2-72.8)</cell><cell cols="2">163.2 (144.1-200.7) 115.0 (65.4-123.8)</cell></row><row><cell>-Beta-lactam antibacterials, penicillins (J01C)</cell><cell>19.5 (13.8-34.4)</cell><cell>15.6 (12.1-38.7)</cell><cell>17.0 (11.5-28.6)</cell><cell>34.1 (30.1-46.2)</cell><cell>17.6 (16.1-20.4)</cell></row><row><cell>-Combinations of penicillins, incl. Beta-lactamase</cell><cell>14.2 (10.6-26.8)</cell><cell>12.2 (9.5-34.3)</cell><cell>10.7 (8.4-16.4)</cell><cell>21.4 (15.9-31.0)</cell><cell>15.2 (13.7-18.3)</cell></row><row><cell>inhibitors (J01CR)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>-Ampicillin and enzyme inhibitor (J01CR01)</cell><cell>5.3 (2.5-16.5)</cell><cell>5.7 (2.8-25.4)</cell><cell>3.8 (2.4-9.7)</cell><cell>11.2 (6.5-17.9)</cell><cell>2.3 (1.0-3.8)</cell></row><row><cell>-Piperacillin and enzyme inhibitor (J01CR05)</cell><cell>6.0 (2.6-9.2)</cell><cell>2.7 (1.6-4.1)</cell><cell>3.1 (2.0-5.8)</cell><cell>10.2 (7.2-12.9)</cell><cell>10.4 (7.4-11.5)</cell></row><row><cell>-Other beta-lactam antibacterials (J01D)</cell><cell>21.6 (16.9-37.5)</cell><cell>18.6 (14.2-29.2)</cell><cell>18.5 (10.3-22.8)</cell><cell>57.5 (45.7-68.5)</cell><cell>20.5 (18.2-34.5)</cell></row><row><cell>-Second-generation cephalosporins (J01 DC)</cell><cell>4 (2.6-11.7)</cell><cell>9.0 (3.4-20.0)</cell><cell>3.3 (1.9-8.2)</cell><cell>4.3 (2.7-17.1)</cell><cell>2.8 (2.1-3.5)</cell></row><row><cell>-Third-generation cephalosporins (J01DD)</cell><cell>3.9 (2.2-6.7)</cell><cell>2.4 (1.2-3.4)</cell><cell>3.1 (2.0-6.4)</cell><cell>9.0 (6.6-12.6)</cell><cell>4.3 (3.5-6.3)</cell></row><row><cell>-Ceftriaxone (J01DD04)</cell><cell>2.6 (1.2-4.7)</cell><cell>1.6 (0.7-2.8)</cell><cell>2.8 (1.5-5.6)</cell><cell>4.7 (2.8-5.8)</cell><cell>1.6 (0.9-2.8)</cell></row><row><cell>-Carbapenems (J01DH)</cell><cell>8.4 (2.3-19.0)</cell><cell>4.6 (1.0-7.5)</cell><cell>3.2 (1.5-8.4)</cell><cell>42.3 (22.5-49.4)</cell><cell>11.8 (10.7-25.7)</cell></row><row><cell>-Meropenem (J01DH02)</cell><cell>7.8 (2.2-16.8)</cell><cell>3.3 (0.8-6.8)</cell><cell>2.5 (1.5-7.8)</cell><cell>40.3 (22.1-45.0)</cell><cell>11.5 (10.4-25.4)</cell></row><row><cell>-Sulfonamides and Trimethoprim (J01E)</cell><cell>2.7 (1.4-5.0)</cell><cell>2.7 (1.4-3.3)</cell><cell>1.1 (0.6-2.0)</cell><cell>4.3 (3.1-7.1)</cell><cell>13.5 (2.7-15.8)</cell></row><row><cell>-Makrolides, lincosamides and streptogramins</cell><cell>7.3 (4.5-9.4)</cell><cell>6.4 (3.4-8.4)</cell><cell>6.2 (4.2-7.8)</cell><cell>8.8 (6.4-10.5)</cell><cell>8.0 (7.0-10.4)</cell></row><row><cell>(J01F)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>-Aminoglycosides (J01G)</cell><cell>0.4 (0.2-1.3)</cell><cell>0.2 (0.1-0.4)</cell><cell>0.2 (0.1-0.6)</cell><cell>3.5 (1.4-7.9)</cell><cell>0.3 (0.2-0.4)</cell></row><row><cell>-Quinolones (J01M)</cell><cell>11.2 (6.8-20.7)</cell><cell>8.3 (6.1-16.0)</cell><cell>7.4 (3.7-12.4)</cell><cell>23.3 (17.9-27.3)</cell><cell>13.5 (10.2-43.6)</cell></row><row><cell>-Ciprofloxacin (J01MA02)</cell><cell>10.5 (6.0-19.0)</cell><cell>8.0 (5.7-14.1)</cell><cell>6.9 (3.1-11.0)</cell><cell>21.6 (17.4-25.2)</cell><cell>11.1 (9.2-41.9)</cell></row><row><cell>-Other antibacterials (J01X)</cell><cell>7.5 (3.5-12.9)</cell><cell>6.1 (3.2-9.3)</cell><cell>3.7 (1.7-6.3)</cell><cell>29.2 (20.8-36.7)</cell><cell>8.8 (5.1-11.0)</cell></row><row><cell>-Glycopeptide antibacterials (J01XA)</cell><cell>3.0 (1.5-8.7)</cell><cell>1.8 (1.4-3.1)</cell><cell>1.7 (0.8-2.2)</cell><cell>12.8 (8.7-19.0)</cell><cell>5.6 (3.7-9.4)</cell></row><row><cell>-Vancomycin (J01XA01)</cell><cell>2.6 (1.5-6.7)</cell><cell>1.8 (1.4-3.1)</cell><cell>1.6 (0.8-2.2)</cell><cell>12.4 (8.7-16.6)</cell><cell>2.8 (2.6-4.0)</cell></row><row><cell cols="5">IQR, interquartile range; VRE, vancomycin-resistant enterococci; ATC, Anatomical Therapeutic Chemical classification system</cell><cell></cell></row><row><cell>a nosocomial and community acquired VRE</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>(including HA-VRE from screening and clinical specimen).</s><s>Results of multivariable analysis for hospital-acquired VRE cases with antibiotic use by antibiotic group (ATC-code 5-digit)</s></p></div></figDesc><table><row><cell>Parameter/category</cell></row></table><note><p><s>DDD Defined daily dose; IRR Incidence rate ratio; CI Confidence interval</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>(including only HA-VRE from clinical specimen).</s><s>Results of multivariable analysis for the frequency of hospital-acquired vancomycin resistant enterococci cases with antibiotic use by antibiotic group (ATC-code 5-digit)</s></p></div></figDesc><table><row><cell>Parameter/category</cell></row></table><note><p><s>DDD Defined daily dose; IRR Incidence rate ratio; CI Confidence interval</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>Not applicable.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head><p><s>95% CI: 95% confidence interval; ATC: Anatomical therapeutic chemical (classification system); CA: Community-acquired; DDD: Defined daily dose; HA: Hospital-acquired; ICU: Intensive care unit; IQR: Interquartile range; IRR: Incidence rate ratio; LOS: Length of stay; PD: Patient-days; VRE: Vancomycinresistant enterococcus</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>No external funding was received for this study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Availability of data and materials</head><p><s>The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</s></p><p><s>Authors' contributions CR, PG and FS were responsible for the study design.</s><s>PG supervised the study.</s><s>MB, LPD and AR were responsible for data collection and data cleaning.</s><s>AK analyzed the microbiological isolates and/or interpreted the results on antimicrobial susceptibility testing.</s><s>FS conducted the statistical analysis.</s><s>All authors interpreted the data, gave important intellectual content and revised the manuscript critically.</s><s>All authors read and approved the final manuscript.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics approval and consent to participate</head><p><s>For this ecologic study, we analyzed aggregated and anonymous data that were collected by the hospital in accordance with the German "Protection against Infection Act", §23.</s><s>Therefore, ethical approval and informed consent were not required and institutional review boards were not consulted.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Consent for publication</head><p><s>Not applicable.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing interests</head><p><s>The authors declare that they have no competing interests.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's Note</head><p><s>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Emergence and spread of vancomycin resistance among enterococci in Europe</title>
		<author>
			<persName><forename type="first">G</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Coque</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hammerum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hope</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hryniewicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Klare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Kristinsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Leclercq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lester</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lillie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Novais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Olsson-Liljequist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">V</forename><surname>Peixe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sadowy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Simonsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Top</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vuopio-Varkila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Willems</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Witte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Woodford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">47</biblScope>
			<biblScope unit="page">19046</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The rise of the enterococcus: beyond vancomycin resistance</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Arias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Murray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Microbiol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="266" to="278" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Webb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Limbago</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Dudeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kallen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Sievert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1288" to="1301" />
			<date type="published" when="2011">2011-2014. 2016</date>
			<publisher>Disease Control and Prevention</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Dramatic increase in vancomycin-resistant enterococci in Germany</title>
		<author>
			<persName><forename type="first">P</forename><surname>Gastmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Behnke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Geffers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1660" to="1664" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Incidence and outcomes associated with infections caused by Vancomycin-resistant enterococci in the United States: systematic literature review and meta-analysis</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Perencevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Samore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Khader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Chorazy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Herwaldt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Blevins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ward</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="203" to="215" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Diazgranados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Zimmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Jernigan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="327" to="333" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics</title>
		<ptr target="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1" />
	</analytic>
	<monogr>
		<title level="j">World Health Organization</title>
		<imprint>
			<date type="published" when="2017-03-03">March 03, 2017. 2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci</title>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cosgrove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1619" to="1628" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Vergis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Hayden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Snydman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Zervos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Linden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Muder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="484" to="492" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Risk factors associated with vancomycin-resistant enterococcus faecium infection or colonization in 145 matched case patients and control patients</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Tornieporth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>John</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hafner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Riley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="767" to="772" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Diazgranados</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Jernigan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">191</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="588" to="595" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management</title>
		<author>
			<persName><forename type="first">T</forename><surname>O'driscoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Crank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Drug Resist</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="217" to="230" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Vancomycin-resistant enterococcal infections</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Murray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="710" to="721" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycinresistant enterococci in four academic medical centers</title>
		<author>
			<persName><forename type="first">U</forename><surname>Stiefel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Pultz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Aron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Donskey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="380" to="383" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Association between vancomycin-resistant enterococci bacteremia and ceftriaxone usage</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mckinnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chamot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Shirley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Moser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Baddley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">G</forename><surname>Pappas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="718" to="724" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">The dynamic relationship between antibiotic use and the incidence of vancomycin-resistant enterococcus: time-series modelling of 7-year surveillance data in a tertiarycare hospital</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">I</forename><surname>Kritsotakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Christidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Roumbelaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tselentis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gikas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="747" to="754" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Non-linear significant relationship between use of glycopeptides and isolation of vancomycin-resistant Enterococcus species in a university hospital setting</title>
		<author>
			<persName><forename type="first">C</forename><surname>Forstner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Diab-Elschahawi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kivaranovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Graninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mitteregger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Macher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wrba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Presterl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infect Control</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">25</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Intensive care antimicrobial resistance epidemiology P, the National Nosocomial Infections Surveillance System H: the effect of vancomycin and third-generation cephalosporins on prevalence of vancomycin-resistant enterococci in 126 U.S. adult intensive care units</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Fridkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Edwards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Courval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Tenover</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lawton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Gaynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Mcgowan</surname><genName>Jr</genName></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="175" to="183" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Does vancomycin prescribing intervention affect vancomycin-resistant enterococcus infection and colonization in hospitals? A systematic review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>De Bruin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Riley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Vancomycin-resistant enterococci: risk related to the use of intravenous vancomycin in a university hospital</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Fuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Harrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Sexton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Colvin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="821" to="823" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Donskey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">K</forename><surname>Chowdhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Hecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Hoyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hanrahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hujer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Hutton-Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Whalen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Rice</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="issue">26</biblScope>
			<biblScope unit="page" from="1925" to="1932" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Low vancomycin MICs and fecal densities reduce the sensitivity of screening methods for vancomycin resistance in enterococci</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Wijesuriya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Perry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pryce</forename><forename type="middle">T</forename><surname>Boehm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Flexman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Coombs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Ingram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Microbiol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2829" to="2833" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">High rate of false-negative results of the rectal swab culture method in detection of gastrointestinal colonization with vancomycin-resistant enterococci</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>D'agata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gautam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Tang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="167" to="172" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Schuts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hulscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Mouton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Verduin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Stuart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Overdiek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Van Der Linden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Natsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Hertogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Wolfs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="847" to="856" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Control of vancomycin-resistant enterococcus in health care facilities in a region</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Ostrowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Trick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Sohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Quirk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Holt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Carson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Hill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Arduino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kuehnert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Jarvis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">344</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="1427" to="1433" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Hospital epidemiology and infection control in acute-care settings</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Sydnor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Perl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Rev</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="141" to="173" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus Aureus and enterococcus</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ledell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Muto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">R</forename><surname>Jarvis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Farr</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="639" to="641" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Healthcare infection control practices advisory C: management of multidrug-resistant organisms in health care settings</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rhinehart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jackson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chiarello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="S165" to="S193" />
			<date type="published" when="2006">2006. 2007</date>
		</imprint>
	</monogr>
	<note>Suppl 2</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillinresistant Staphylococcus Aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Microbiol Immunol Infect</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="431" to="436" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Antibiotic consumption and resistance: data from Europe and Germany</title>
		<author>
			<persName><forename type="first">E</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gastmeier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Schwab</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Med Microbiol</title>
		<imprint>
			<biblScope unit="volume">303</biblScope>
			<biblScope unit="issue">6-7</biblScope>
			<biblScope unit="page" from="388" to="395" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli</title>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Samore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1462" to="1468" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Multidrug-resistant organisms detected more than 48 hours after hospital admission are not necessarily hospitalacquired</title>
		<author>
			<persName><forename type="first">S</forename><surname>Erb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Frei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dangel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Widmer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="18" to="23" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<monogr>
		<title level="m" type="main">WHO: Defined Daily Dose -Definition and general considerations</title>
		<ptr target="https://www.whocc.no/ddd/definition_and_general_considera/.Acessedon20" />
		<imprint>
			<date type="published" when="2015">July 2017. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
